Ji Xi Shi

Researchers are studying the gut microbiome in people with several serious chronic diseases in China, including various cancers, hypertension, epilepsy, and kidney disease. The study aims to better understand the differences and similarities in gut microbiome patterns linked to these diseases and different regions, and how these patterns affect microbiome-based diagnostic tests. This work is important because past research has shown links between microbial imbalances and disease, but variability between studies has made it hard to draw clear conclusions. This observational study will recruit 500 patients diagnosed with each target disease and 500 healthy control participants matched by age and sex. Researchers will collect detailed information about participants' demographics, lifestyle, diet, medications, and health status. Biological samples including feces, saliva, urine, and blood will be collected for analysis. There is no active treatment or intervention; the study focuses on characterizing the microbiome and related health data. Participants will undergo assessments of their medical history and lifestyle, with sample collections to analyze microbiome and biochemical markers. Researchers will measure the baseline microbiome to identify disease-associated signatures. The study requires participants to be aged 18 to 75 and to have lived in the hospital's province for at least three years. Safety monitoring is observational, with no study treatments given. The total participant involvement includes data and sample collection for cross-sectional analysis.

Researchers are evaluating the use of albumin combined with endovascular treatment in patients who have acute ischemic stroke affecting the anterior circulation. This phase 3, multicenter, open-label clinical trial aims to verify the safety and effectiveness of adding albumin to reperfusion therapy for these patients. The study enrolls adults aged 18 to 80 years who have had a large vessel occlusion stroke and meet specific clinical criteria. Participants are randomly assigned to one of two groups: one group receives albumin together with endovascular therapy, and the other group receives endovascular therapy alone. Albumin is administered intravenously at a dose of 0.5 g/kg (up to 37.5 g) on the first day and then daily on days two, three, and four. All patients receive standard acute stroke treatment and secondary prevention according to current American stroke guidelines. Initial evaluations include brain imaging (CT or MRA) to locate the blockage and check for bleeding, as well as laboratory tests and stroke severity scoring. Throughout the study, vital signs and neurological assessments are recorded. After 90 days from randomization, patients are followed up by telephone to assess recovery using quality of life scales and functional outcomes. The main measure of success is the proportion of patients achieving a good functional status or returning to their baseline level at 90 days. Safety and efficacy are carefully monitored during this period to understand the impact of albumin therapy in this patient population.

This research investigates how weight loss through a diet management mobile app and an intelligent weight scale affects cardiovascular health in obese patients with heart failure. The study focuses on patients with heart failure with reduced ejection fraction and aims to see if these tools can reduce death rates, hospital stays related to heart failure, and improve frailty and quality of life. The trial addresses a gap where current heart failure guidelines recognize obesity as a risk but lack effective interventions for this group. Participants are randomly assigned to one of two groups: one group uses a fully functional diet management app and intelligent weight scale designed to support weight loss in obese heart failure patients, while the other group uses limited-function versions of the app and scale as a comparison. Both groups use the app at every meal and the scale daily for 12 months. The trial is a multicenter, single-blind randomized controlled study. During the study, participants will visit the clinic after 12 months for checkups. Researchers will collect data on a composite cardiovascular outcome, including all-cause mortality and hospitalizations related to heart failure, tracked over one year. Adherence to app and scale use is monitored through the mobile application. The study measures the impact on heart failure frailty, quality of life, and overall cardiovascular outcomes over the trial period.